{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"3.5","value":"0.5"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"6.9","value":"3.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"255"}],"units":"Participants"}],"description":"Proven or probable invasive aspergillosis (IA) is defined according to the criteria developed by the EORTC/MSG. Kaplan Meier approach will used to estimate the incidence.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive caspofungin acetate IV over one hour QD beginning within 24-72 hours following the last dose of chemotherapy for each course. and continuing until ANC \\> 100-500/uL following the nadir or the next chemotherapy course begins.\n\nCaspofungin Acetate: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Arm I (Caspofungin Acetate)"},{"description":"Patients receive fluconazole IV over 1-2 hours or PO QD beginning within 24-72 hours following the last dose of chemotherapy for each course.\n\nFluconazole: Given IV or PO\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG001","title":"Arm II (Fluconazole)"}],"paramType":"NUMBER","populationDescription":"Evaluable patients (ineligible and inevaluable due to having IFI before IFI monitoring period were excluded)","reportingStatus":"POSTED","timeFrame":"Up to 5 months since enrollment","title":"Percentage of Participants With Proven or Probable Invasive Aspergillosis (IA)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}